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Expanded Abstract 
Citation 
Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, 
Rossaint R, Axelsen M, Kluger Y: Recombinant factor VIIa 
as adjunctive therapy for bleeding control in severely injured 
trauma patients: two parallel randomized, placebo-
controlled, double-blind clinical trials. J Trauma 2005, 59:8-
15 [1]. 
Background 
Uncontrolled bleeding is a leading cause of death in trauma. 
Two randomized, placebo-controlled, double-blind trials 
(one in blunt trauma and one in penetrating trauma) were 
conducted simultaneously to evaluate the efficacy and 
safety of recombinant factor VIIa (rFVIIa) as adjunctive 
therapy for control of bleeding in patients with severe blunt 
or penetrating trauma. 
Methods 
Design:  Two parallel randomized, placebo-controlled, 
double-blind clinical trials.  
Setting: Thirty-two hospitals throughout Australia, Canada, 
France, Germany, Israel, Singapore, South Africa, and the 
United Kingdom. 
Intervention:  Severely bleeding trauma patients were 
randomized to rFVIIa (200, 100, and 100 µg/kg) or placebo 
in addition to standard treatment. The first dose followed 
transfusion of the eighth red blood cell (RBC) unit, with 
additional doses 1 and 3 hours later. 
Outcomes: The primary endpoint for bleeding control in 
patients alive at 48 hours was units of RBCs transfused 
within 48 hours of the first dose. 
Results 
Among 301 patients randomized, 143 blunt trauma patients 
and 134 penetrating trauma patients were eligible for 
analysis. In blunt trauma, RBC transfusion was significantly 
reduced with rFVIIa relative to placebo (estimated reduction 
of 2.6 RBC units, p = 0.02), and the need for massive 
transfusion (>20 units of RBCs) was reduced (14% vs. 33% 
of patients; p = 0.03). In penetrating trauma, similar 
analyses showed trends toward rFVIIa reducing RBC 
transfusion (estimated reduction of 1.0 RBC units, p = 0.10) 
and massive transfusion (7% vs. 19%; p = 0.08). Trends 
toward a reduction in mortality and critical complications 
were observed. Adverse events including thromboembolic 
events were evenly distributed between treatment groups.  
Conclusion 
Recombinant FVIIa resulted in a significant reduction in 
RBC transfusions in severe blunt trauma. Similar trends 
were observed in penetrating trauma. The safety of rFVIIa 
was established in these trauma populations within the 
investigated dose range. 
Commentary 
Uncontrolled bleeding is a major cause of death in trauma. 
Considerable controversy exists regarding the role of 
recombinant activated factor VIIa (rFVIIa) for the control of 
severe hemorrhage in trauma, although case series and 
anecdotal reports have shown promise [2-5]. Dr. Boffard 
and colleagues [1] confronted this issue by carrying out two 
relatively large prospective, randomized clinical trials of 
rFVIIa in severely bleeding trauma victims. One trial 
enrolled patients with severe blunt trauma (n=143) and the 
other enrolled patients with penetrating trauma (n=134). The 
authors reported a statistically significant reduction in red 
blood cell (RBC) transfusion and the need for massive (>20 
unit) transfusion in blunt trauma patients treated with rFVIIa.  
There was a trend favoring rFVIIa in the penetrating trauma 
group. There were no differences in adverse events, such 
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as thromboembolism or mortality, between the treatment 
groups in either of the studies. The observed treatment 
effect was independent of clinical center. 
This complex, international, multi-center study was a 
carefully planned experimental trial with clinically relevant 
findings. There are, however, several limitations that 
deserve consideration. To be eligible for this trial, patients 
had to have evidence of severe bleeding (transfusion of at 
least 6 units of RBCs within 4 hours of admission). 
Fortunately, few trauma patients meet this requirement [6].  
Therefore, the results of this trial are applicable to a 
relatively small subset of trauma patients. The drug seemed 
to work best after blunt trauma rather than penetrating 
trauma. The authors suggest this observation may reflect 
that blunt trauma is more often associated with diffuse 
(“nonsurgical”) bleeding, whereas penetrating trauma is 
more often associated with major arterial or venous injuries 
that require surgical, as opposed to pharmacologic, control. 
In order to be included in the primary analysis, patients had 
to be alive 48 hours after the first dose of study drug. This 
requirement was necessitated by the study’s primary 
endpoint; patients who die early have less time to be 
transfused, so a drug that helps patients to live longer could 
paradoxically increase the likelihood for transfusion. In other 
words, for the comparison to be fair, subjects had to have 
equal time at risk. While this is entirely appropriate, it does 
make interpreting the number needed to treat (NNT) to 
avoid massive transfusion a bit challenging. Since the 
reported NNT actually represents the number of non-dead 
patients that would need to be treated, this number is only 
useful if one could know in advance who will live or die 
within 48 hours. Therefore, it would have been helpful for 
the authors to have also reported the NNT for all patients. In 
secondary analyses, the authors did explore the effect of 
including all patients. While the between-group differences 
were no longer significant, the direction of the effect 
remained the same. 
The authors used a one-sided statistical test to analyze the 
RBC transfusion data because “it was not expected that 
administration of rFVIIa would increase transfusion 
requirements.” In general, one-sided p-values are often 
viewed with skepticism by statisticians and clinicians. If the 
authors’ aim was to change practice, they might have 
presented a more convincing argument by using a two-
sided approach instead. The study was not powered to 
detect a mortality difference, although 30-day mortality was 
non-significantly lower for rFVIIa treated patients (blunt 
trauma: 25% vs. 30%, p=0.58; penetrating trauma: 24% vs. 
28%, p=0.69). With a larger trial, these differences might 
have become significant, which would have made the 
approximate $20,000 cost of the drug regimen easier for 
clinicians (and pharmacy and therapeutic committees) to 
justify. To enable more judicious and, perhaps, more cost-
effective use of this drug, it would be useful to establish 
criteria to predict when rFVIIa might be futile, such as in the 
setting of profound acidosis and coagulopathy [7]. 
Recommendation 
The finding that rFVIIa may reduce RBC transfusions is 
important but only lends credence to the argument that 
further trials are needed. Questions regarding minimal 
effective dose, number and frequency of doses, and the 
indicated patient population (and conversely, the population 
which would not benefit from this drug) creates a field ripe 
for further exploration. Given its expense, formal cost-
effectiveness analyses should be an integral component of 
all future trials. 
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